Brief: Kintor Gets NMPA Approval For Trials Of Proxalutamide To Treat COVID-19 In China

Kintor Pharmaceutical

01/09/2021 05:34

Sept 1 (Reuters) - Kintor Pharmaceutical Ltd  9939.HK :
    * GOT APPROVAL FROM NMPA OF CHINA FOR TWO PHASE III CLINICAL
TRIALS OF PROXALUTAMIDE FOR TREATING COVID-19 INFECTIONS IN
CHINA
    * ONE PHASE III TRIAL TO BE CONDUCTED FOR PROPOSED TREATMENT
OF
MILD/MODERATE MALE COVID-19 PATIENTS IN CHINA, BRAZIL, MALAYSIA,
PHILIPPINES
    * ANOTHER PHASE III TRIAL TO BE CONDUCTED TO TREAT
HOSPITALISED
COVID-19 PATIENTS IN US, CHINA, SOUTH AMERICA, EUROPE AND INDIA

Source text for Eikon:  ID:nHKS4mBN7J 
Further company coverage:  9939.HK 

 ((Reuters.Briefs@thomsonreuters.com;))